Houte Hans Van Sells 1,387 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 1,387 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $12.04, for a total value of $16,699.48. Following the completion of the transaction, the chief financial officer now directly owns 71,832 shares of the company’s stock, valued at $864,857.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Friday, February 16th, Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $68,256.24.

Nurix Therapeutics Stock Up 8.8 %

Nurix Therapeutics stock opened at $13.08 on Thursday. Nurix Therapeutics, Inc. has a twelve month low of $4.22 and a twelve month high of $18.12. The stock’s fifty day simple moving average is $13.76 and its 200-day simple moving average is $9.86.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The company had revenue of $15.16 million for the quarter, compared to analysts’ expectations of $30.66 million. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. On average, analysts predict that Nurix Therapeutics, Inc. will post -3.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in NRIX. Charles Schwab Investment Management Inc. lifted its holdings in Nurix Therapeutics by 48.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 568,576 shares of the company’s stock worth $4,469,000 after buying an additional 184,617 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Nurix Therapeutics by 351.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock valued at $58,000 after buying an additional 4,367 shares during the last quarter. Kennedy Capital Management LLC boosted its holdings in shares of Nurix Therapeutics by 192.7% in the third quarter. Kennedy Capital Management LLC now owns 163,623 shares of the company’s stock valued at $1,286,000 after acquiring an additional 107,719 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Nurix Therapeutics by 40.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 183,923 shares of the company’s stock worth $1,446,000 after acquiring an additional 53,429 shares during the last quarter. Finally, ARK Investment Management LLC increased its holdings in shares of Nurix Therapeutics by 23.2% in the 4th quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock valued at $32,972,000 after acquiring an additional 601,952 shares during the period.

Analyst Upgrades and Downgrades

NRIX has been the subject of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, April 9th. Robert W. Baird upped their price objective on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a report on Thursday, April 11th. HC Wainwright lowered their price target on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. Morgan Stanley lifted their price objective on Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. Finally, Royal Bank of Canada increased their target price on Nurix Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a research note on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.33.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.